JP2008513469A5 - - Google Patents

Download PDF

Info

Publication number
JP2008513469A5
JP2008513469A5 JP2007532470A JP2007532470A JP2008513469A5 JP 2008513469 A5 JP2008513469 A5 JP 2008513469A5 JP 2007532470 A JP2007532470 A JP 2007532470A JP 2007532470 A JP2007532470 A JP 2007532470A JP 2008513469 A5 JP2008513469 A5 JP 2008513469A5
Authority
JP
Japan
Prior art keywords
toremifene
use according
dose
day
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007532470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513469A (ja
Filing date
Publication date
Priority claimed from US10/944,465 external-priority patent/US20050080143A1/en
Application filed filed Critical
Publication of JP2008513469A publication Critical patent/JP2008513469A/ja
Publication of JP2008513469A5 publication Critical patent/JP2008513469A5/ja
Pending legal-status Critical Current

Links

JP2007532470A 2004-09-20 2005-09-19 アンドロゲン除去によって生じる骨粗鬆症の治療 Pending JP2008513469A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/944,465 US20050080143A1 (en) 2001-11-29 2004-09-20 Treatment of androgen-deprivation induced osteoporosis
PCT/US2005/032998 WO2006033979A1 (en) 2004-09-20 2005-09-19 Treatment of androgen - deprivation induced osteoporosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008240566A Division JP2009029823A (ja) 2004-09-20 2008-09-19 アンドロゲン除去によって生じる骨粗鬆症の治療

Publications (2)

Publication Number Publication Date
JP2008513469A JP2008513469A (ja) 2008-05-01
JP2008513469A5 true JP2008513469A5 (enExample) 2010-04-22

Family

ID=36090335

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007532470A Pending JP2008513469A (ja) 2004-09-20 2005-09-19 アンドロゲン除去によって生じる骨粗鬆症の治療
JP2008240566A Pending JP2009029823A (ja) 2004-09-20 2008-09-19 アンドロゲン除去によって生じる骨粗鬆症の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008240566A Pending JP2009029823A (ja) 2004-09-20 2008-09-19 アンドロゲン除去によって生じる骨粗鬆症の治療

Country Status (12)

Country Link
US (1) US20050080143A1 (enExample)
EP (2) EP1796643A4 (enExample)
JP (2) JP2008513469A (enExample)
KR (1) KR20070059167A (enExample)
CN (2) CN101961327A (enExample)
AU (1) AU2005287113B2 (enExample)
BR (1) BRPI0515668A (enExample)
CA (1) CA2581159A1 (enExample)
EA (1) EA014309B1 (enExample)
IL (1) IL182091A0 (enExample)
MX (1) MX2007003272A (enExample)
WO (1) WO2006033979A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
CN116869944A (zh) * 2023-08-15 2023-10-13 重庆士立德医药科技有限公司 一种托瑞米芬组合物及其制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2464203A (en) 1943-05-21 1949-03-15 Boots Pure Drug Co Ltd Manufacture of dienoestrol
US2465505A (en) 1944-12-05 1949-03-29 Hoffmann La Roche Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4
US2914562A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of triphenylethanol
GB8508404D0 (en) * 1985-03-30 1985-05-09 Baylor College Medicine Therapeutic compositions
US4897254A (en) * 1984-09-21 1990-01-30 The Dow Chemical Company Radioactive compositions for the treatment of calcific tumors
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
FR2578113B1 (fr) * 1985-02-25 1988-04-15 Merlin Gerin Declencheur statique numerique a fonctions optionnelles pour un disjoncteur electrique
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
ES2189784T3 (es) * 1989-07-07 2003-07-16 Endorech Inc Procedimiento para el tratamiento de enfermedades relacionadas con adrogenos.
US5153622A (en) * 1989-08-03 1992-10-06 Asahi Kogaku Kogyo Kabushiki Kaisha Pressure alarm for water-sealed camera
JPH06287885A (ja) * 1991-04-15 1994-10-11 Yamauchi Corp 脱水プレス用エンドレスベルト
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
TW303299B (enExample) * 1993-07-22 1997-04-21 Lilly Co Eli
TW403738B (en) * 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
CA2248769A1 (en) * 1996-03-18 1997-09-25 The Trustees Of The University Of Pennsylvania Bioactive material substrate for enhanced cellular attachment and function
GB9712086D0 (en) * 1997-06-10 1997-08-13 Bp Chem Int Ltd Process for preparing polyketones
US6096764A (en) * 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
EP2277514A1 (en) * 1998-05-07 2011-01-26 The University Of Tennessee Research Corporation A method for chemoprevention of prostate cancer
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6410043B1 (en) * 1998-05-07 2002-06-25 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
EP1102755B1 (en) * 1998-08-07 2006-01-04 Chiron Corporation Substituted isoxazole derivatives as estrogen receptor modulators
US6165504A (en) * 1998-09-23 2000-12-26 Barr Laboratories, Inc. Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients
US6258802B1 (en) * 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
CN1400904A (zh) * 2000-01-28 2003-03-05 恩多研究公司 与雌激素联合的选择性雌激素受体调节剂
US6855703B1 (en) * 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
EP1289519B1 (en) * 2000-05-26 2019-02-13 Harry Fisch Methods of treating androgen deficiency in men using clomiphene
AU2001288213B2 (en) * 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
US20030114420A1 (en) * 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
US20030158160A1 (en) * 2000-07-05 2003-08-21 Barrington Furr Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
PT1210951E (pt) * 2000-11-30 2005-04-29 Pfizer Prod Inc Composicao que contem agonistas/antagonistas de estrogeneo e testosterona para tartamento de um declinio do nivel da hormona testosterona
US6413633B1 (en) * 2001-04-18 2002-07-02 Francis Patrick McCullough Activated biregional fiber(s)
WO2002091993A2 (en) * 2001-05-10 2002-11-21 Merck & Co., Inc. Estrogen receptor modulators
DE02726901T1 (de) * 2001-05-17 2004-07-15 Immunex Corp., Seattle Therapeutische verwendung von rang-antagonisten
DK1666033T3 (da) * 2001-11-29 2009-04-06 Gtx Inc Forebyggelse og behandling af ved androgenmangel fremkaldt osteoporose
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20040152733A1 (en) * 2002-03-15 2004-08-05 Wallace Owen Brendan Duloxetine for treatment of hot flashes
KR20050049476A (ko) * 2002-08-14 2005-05-25 파마시아 앤드 업존 캄파니 엘엘씨 홍조를 치료하기 위한 레복세틴의 용도
JP4115913B2 (ja) * 2002-08-23 2008-07-09 エーエスエムエル ネザーランズ ビー.ブイ. リソグラフィ投影装置及び前記装置で使用する微粒子バリヤ
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20070042040A1 (en) * 2003-04-30 2007-02-22 Herve Porchet Methods and compositions using gonadotropin hormone releasing hormone
US7048210B2 (en) * 2003-05-21 2006-05-23 Frank Clark Showerhead with grooved water release ducts
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof

Similar Documents

Publication Publication Date Title
FI3788047T3 (fi) Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
JP2013541583A5 (enExample)
JP2011503063A5 (enExample)
NZ595189A (en) Combination therapy with thiocolchicine derivatives
JP2016185995A5 (enExample)
JP2011068653A5 (enExample)
JP2013509444A5 (enExample)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2017506624A5 (enExample)
JP2015515985A5 (enExample)
JP2012193216A5 (enExample)
FI3000467T3 (fi) Rintasyöpähoitokuuri, jossa käytetään neratinibia
ME02474B (me) Terapijski režimi
HRP20171742T4 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
JP2015508765A5 (enExample)
JP2008513469A5 (enExample)
JP2016507500A5 (enExample)
JP2005519936A5 (enExample)
RU2018119085A (ru) Схема введения ингибитора фосфатидилинозитол-3-киназы
RU2016116915A (ru) Комбинация
HRP20251123T1 (hr) Ekopipam za liječenje touretteovog sindroma
JP2012517459A5 (enExample)
JP2012041314A5 (enExample)
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.